Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Advances in Therapy|March 14, 2019
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular TestingKumar Prabhash, Suresh H Advani, Ullas Batra, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Comprehensive Development and Implementation of Good Laboratory Practice for NGS Based Targeted Panel on Solid Tumor FFPE Tissues in DiagnosticsAnuradha Chougule, Vinita Jagtap, Ankita Nikam, et al.
Ecancermedicalscience|August 3, 2022
Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancerGoutam Santosh Panda, Vanita Noronha, Darshit Shah, et al.
Frontiers in Cell and Developmental Biology|November 17, 2022
Integrated proteomics and phosphoproteomics revealed druggable kinases in neoadjuvant chemotherapy resistant tongue cancerIrene A George, Gajanan Sathe, Vivek Ghose, et al.
Ebiomedicine|May 24, 2016
Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside StudyEddy Pasquier, Nicolas André, Janine Street, et al.
Plos One|September 17, 2016
ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing CountryVanita Noronha, Anant Ramaswamy, Vijay M Patil, et al.
Clinical Lung Cancer|June 1, 2022
Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLCVichitra Behel, Anuradha Chougule, Vanita Noronha, et al.
BJC Reports|November 8, 2024
Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settingsAmit Kumar, Akhil Kapoor, Vanita Noronha, et al.
Ecancermedicalscience|September 27, 2021
An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settingsAkhil Kapoor, Vanita Noronha, Amit Joshi, et al.
JTO Clinical and Research Reports|January 19, 2023
Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained SettingsAkhil Kapoor, Vanita Noronha, Vijay Patil, et al.
Pageof 4